
## Liwen Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10169135/publications.pdf Version: 2024-02-01



LINDEN SU

#	Article	IF	CITATIONS
1	Multiâ€omics consensus ensemble refines the classification of muscleâ€invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies. Clinical and Translational Medicine, 2021, 11, e601.	4.0	25
2	Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 723817.	3.7	9
3	A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect. Statistical Methods in Medical Research, 2021, 30, 904-915.	1.5	5
4	Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials. JCO Precision Oncology, 2022, 6, e2100394.	3.0	4
5	M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect. Statistics in Medicine, 2022, 41, 815-830.	1.6	3
6	Power prior for borrowing the real-world data in bioequivalence test with a parallel design. International Journal of Biostatistics, 2021, .	0.7	1
7	Dynamic prediction of disease processes based on recurrent history and functional principal component analysis ofÂlongitudinal biomarkers: Application for ovarian epithelial cancer. Statistics in Medicine, 2021, 40, 2006-2023.	1.6	0
8	Detection and prediction of active ingredients in fingerprints of traditional Chinese medicine from a highâ€dimensional perspective. Journal of Chemometrics, 2021, 35, e3347.	1.3	0
9	An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-13.	1.9	0
10	Bayesian twoâ€stage sequential enrichment design for biomarkerâ€guided phase II trials for anticancer therapies. Biometrical Journal, 2022, , .	1.0	0